Intensivmedizin - Nach den positiven Studien kommen die Fragen

Literatur

• 1 Andrews P, Azoulay E, Antonelli L. et al . Acute respiratory failure and acute lung injury, ventilation, hemodynamics, education, renal failure.  Intensive Care Med. 2006;  32 207-216
• 2 Andrews P, Azoulay E, Antonelli L. et al . Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury.  Intensive Care Med. 2006;  32 380-390
• 3 Andrews P, Azoulay E, Antonelli L. et al . Nutrition, pediatric and neonatal critical care, and experimental.  Intensive Care Med. 2006;  32 490-500
• 4 Annane D, Sebille V, Charpentier C. et al . Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.  JAMA. 2002;  288 862-871
• 5 Annane D, Bellissant E, Bollaert P, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating severe sepsis and septic shock.  Cochrane Database Syst Rev. 2004;  CD002243-1
• 6 Briegel J, Forst H, Haller M. et al . Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, doubleblind, single-center study.  Crit Care Med. 1999;  27 723-732
• 7 Brunkhorst F M, Kuhnt E, Engel C. et al . Intensive insulin therapy in patients with severe sepsis and septic shock is associated with an increased rate of hypoglycemia - results from a randomized multicenter study (VISEP).  Infection. 2005;  33 19-20
• 8 Cleland J G, Freemantle N, Coletta A P, Clark A L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE II, SURVIVE, and PROACTIVE.  Eur J Heart Fail. 2006;  8 105-110
• 9 Cotter G, Kaluski E, Blatt A. et al . L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock.  Circulation. 2000;  101 1358-1361
• 10 Cotter G, Kaluski E, Milo O. et al . LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study.  Eur Heart J. 2003;  24 1287-1295
• 11 Dellinger R P, Carlet J M, Masur H. et al. for the Surviving Sepsis Campaign Management Guidelines Committee . Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.  Crit Care Med. 2004;  32 858-873
• 12 Granger C B, Mahaffey K W, Weaver W D. et al. for the COMMA investigators . The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.  Circulation. 2003;  108 1184-1190
• 13 Hochman J S. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm.  Circulation. 2003;  107 2998-3002
• 14 Hochman J S, Sleeper L A, Webb J G. et al. for the SHOCK Investigators . Early revascularisation in acute myocardial infarction complicated by cardiogenic shock.  N Engl J Med. 1999;  341 625-634
• 15 Hochman J S, Buller C E, Sleeper L A. et al . Cardiogenic shock complicating acute myocardial infarction - etiologies, management and outcome: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shocK?.  Am Coll Cardiol. 2000;  36 (Suppl A) 1063-1070
• 16 Hochman J S, Sleeper L A, White H D. et al . One-year survival following early revascularization for cardiogenic shock.  JAMA. 2001;  285 190-192
• 17 Keh D, Boehnke T, Weber-Cartens S. et al . Immunologic and hemodynamic effects of „low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study.  Am J Respir Crit Care Med. 2003;  167 512-520
• 18 Kohsaka S, Menon V, Lowe A M, Lange M, Dzavik V, Sleeper L A, Hochman J S. SHOCK Investigators . Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock.  Arch Intern Med. 2005;  165 1643-1650
• 19 Mehta S R, Yusuf S, Diaz R. et al. CREATE-ECLA Trial Group Investigators . Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial.  JAMA. 2005;  293 437-446
• 20 Reinhart K, Brunkhorst F M, Bone H -G. et al . S-2 Leitlinien der Deutschen Sepsis-Gesellschaft e. V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin unter Mitwirkung weiterer Fachgesellschaften. Diagnose und Therapie der Sepsis.  Intensiv-News. 2006;  10 (Suppl 2) 1-20
• 21 Prondzinsky R, Werdan K, Buerke M. Kardiogener Schock: Pathomechanismen, klinischer Verlauf, therapeutische Ansätze und Perspektiven.  Internist. 2004;  45 284-295
• 22 Riou B, Cittanova M L. An international review of HES.  Intensive Care Med. 1999;  25 1340
• 23 Schortgen F, Lacherade J C, Bruneel F. et al . Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study.  Lancet. 2001;  357 911-916
• 24 Schwertz H, Müller-Werdan U, Prondzinsky R, Werdan K, Buerke M. Katecholamin-Therapie im kardiogenen Schock: hilfreich, nutzlos oder gefährlich?.  Dtsch Med Wochenschr. 2004;  129 1925-1930
• 25 Van den Berghe G, Wouters P, Weekers F. et al . Intensive insulin therapy in critically ill patients.  N Engl J Med. 2001;  345 1359-1367
• 26 Van den Berghe G, Wilmer A, Hermans G. et al . Intensive insulin therapy in the medical ICU.  N Engl J Med. 2006;  354 449-461
• 27 Dellinger R P. 26th International symposium on Intensive care and Emergency Medicine, Brüssel, 21.-24. März 2006. 
• 28 www.ClinicalTrials.gov, Identifier: NCT00135473.